STUDresearch · Peptide
Testagen
Also known as
KEDG peptide · KEDG · Lys-Glu-Asp-Gly · H-Lys-Glu-Asp-Gly-OH · H-KEDG-OH · testicular bioregulator · Testagen Cytogen · Anterior Pituitary Peptide (APP) (vendor label discussions) · Khavinson testis tetrapeptide · testis peptide bioregulator
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Mixed
Oral / SubQ / IM
Longevity & bioregulators
Mixed — marketed for reproductive and hormone-related bioregulator effects, with oral or injectable exposure; not a local injury-site agent.
What people say
Testagen is the KEDG tetrapeptide in Khavinson-style endocrine bioregulator discussion. It is not testosterone, Testoluten extract, hCG or a proven substitute for hypogonadism care.
Doses people talk about
These formats are not interchangeable. Finished capsule mass does not establish pure KEDG content, and no row is a progression.
How it may feel
Most legacy notes describe a subtle or absent acute feel. One three-month account reported energy, libido and strength changes but unchanged total testosterone amid several other peptides.
Western research-chart band~100–300 mcg SubQ once daily
A gray-market chart range, distinct from classic short milligram courses.
Classic short-course discussion~1–2 mg SubQ or IM daily
Usually paired with about 10–20 consecutive days in Khavinson-style course descriptions.
Observed intermittent account2 mg M/W/F, then every 3 days, later M/W/F again
One same-author account across about three months; the poster also used Reta, CJC/Ipamorelin, MOTS-c and occasional BPC/TB-500.
Half-life & effect duration
- Half-life in the body
- Secondary / community estimateAbout 30 minutes
- Felt duration people report
- One multi-peptide accountMore energy, libido and strength over weeks to 3 months
Cycles people discuss
Classic 10–20-day and oral month-long blocks coexist with 4–8-week microgram charts and intermittent re-runs. They are community traditions, not schedules derived from human PK.
Timing
Morning SubQ use is common in community charts; oral schedules vary between before meals and with food, sometimes split across the day. These are product- and chart-specific habits, not a shared timing rule.
Stacks
Epitalon, Thymalin, other organ bioregulators and HPG agents appear around Testagen. The inspected positive account also used Reta, CJC/Ipamorelin, MOTS-c and BPC/TB-500, preventing attribution.
Watch for
Injection site: Redness, itch, swelling, or tenderness — the most consistently noted community effect for SubQ bioregulator use; usually short-lived with rotation and sterile technique.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No validated human plasma half-life for synthetic KEDG was established in the reviewed evidence.
The inspected laboratory paper identifies Testagen as Lys-Glu-Asp-Gly and studies peptide-histone binding, not absorption, plasma concentration or clearance. The community schedule therefore cannot supply PK.
Absence of PK in the reviewed lab paper and community thread is not proof that no unpublished or inaccessible data exist; the legacy secondary minute-scale claims remain preserved as unvalidated.
- Fedoreyeva et al.: Interaction of Short Peptides with FITC-Labeled Wheat Histones and Their Complexes with Deoxyribooligonucleotides (opens in a new tab)Full 10-page PDF inspected. PDF page 2 identifies Testagen as Lys-Glu-Asp-Gly in the methods; PDF pages 3–4 describe the fluorescence-quenching analysis and table of peptide-histone Stern–Volmer constants. The paper contains no human administration or concentration-time study.Originator-adjacent in-vitro binding work; it establishes sequence and laboratory interaction context, not endocrine efficacy, bioavailability or human pharmacokinetics.
- Testagen peptide: research protocols, mechanisms and hormonal reset support (opens in a new tab)Read the complete visible thread, especially F-Everything1992's week-three, next-update and about-three-month reports: 2 mg M/W/F, then every three days, then M/W/F again; perceived energy, libido and strength; total testosterone still in the low 700s; a planned break; and disclosed Reta, CJC/Ipamorelin, MOTS-c and occasional BPC/TB-500. Also read the separate 1 mg/day reply.Self-reported labs and unverified product; multiple co-exposures and schedule changes prevent attribution. The planned off-period had no visible same-author outcome follow-up at inspection.
Felt duration people report
A same-author account reported changes over weeks to three months, but no per-dose onset or offset was established.
The poster reported higher energy, libido and strength after beginning at 2 mg M/W/F, then reported 2 mg every three days, and at about three months said they were again taking 2 mg M/W/F; total testosterone remained in the low 700s while multiple concurrent peptides continued.
One uncontrolled, changing schedule with Reta, CJC/Ipamorelin, MOTS-c and occasional BPC/TB-500; no verified post-break update or causal attribution.
- Testagen peptide: research protocols, mechanisms and hormonal reset support (opens in a new tab)Read the complete visible thread, especially F-Everything1992's week-three, next-update and about-three-month reports: 2 mg M/W/F, then every three days, then M/W/F again; perceived energy, libido and strength; total testosterone still in the low 700s; a planned break; and disclosed Reta, CJC/Ipamorelin, MOTS-c and occasional BPC/TB-500. Also read the separate 1 mg/day reply.Self-reported labs and unverified product; multiple co-exposures and schedule changes prevent attribution. The planned off-period had no visible same-author outcome follow-up at inspection.
What people say
- T support claims (community): Framed as helping endogenous testosterone when production is low or age-declining — bioregulator “nudge,” not TRT-level serum jumps. forum
- Libido / drive anecdotes: Multi-week course logs of better sex drive or bedroom performance; heavily confounded by sleep, fat loss, stacks, and expectancy. anecdote
- TSH → T3/T4 cascade narrative: Vendor and review pages claim pituitary stimulation of TSH with downstream thyroid hormone normalization; human PK/PD packages for synthetic KEDG remain thin. forum
- T via thyroid linkage hypothesis: Hypothyroidism is known to drag free T; some writeups argue Testagen’s T story may be partly indirect through thyroid axis improvement rather than pure Leydig-cell push. forum
- Energy / recovery logs: Mild, non-stimulant energy or training-recovery notes during or after a course. anecdote
- Fertility / sperm talk: Community and marketing frame HPG support without the fertility suppression of exogenous T; controlled sperm-parameter trials for synthetic Testagen are sparse. forum
- vs TRT (positioning): Cast as subtle, fertility-friendlier bioregulator vs replacement — a product narrative, not a head-to-head noninferiority trial. forum
- Prostatitis / urogenital writeups: Older clinical narratives in chronic abacterial prostatitis contexts cite better uroflow, less inflammation signals, and serum T shifts in treated cohorts — specific population, not general men’s-health RCTs. trial
- Thyroid / pituitary (animal): Hypophysectomized chicken models (Kuznik et al.) report Lys-Glu-Asp-Gly helping restore thyroid morphology and hormonal activity after pituitary removal — stronger restoration noted in younger vs older birds in related work. animal
- Gene-expression / DNA work: Short Khavinson peptides (including related sequences) show nuclear penetration and DNA/oligonucleotide interaction in HeLa and similar systems (e.g. PMID 22117547 family). lab
- Immune / hemostasis secondary talk: Originator-line and collaborator work discusses immune-cell differentiation and clotting-normalization narratives alongside endocrine effects — not the main bro search intent. trial
- What it is not proven for: No high-quality Western evidence that synthetic KEDG cures hypogonadism, replaces TRT, treats infertility, or extends human lifespan. trial
Doses people talk about
- Identity first: Confirm synthetic KEDG lyophilized vial vs Cytogen-class oral capsule vs Testoluten extract before copying any number. Finished oral product mass ≠ pure free-peptide milligrams. forum
- Conservative micro start: ~100 mcg subq morning × ~4–6 weeks before titrating, in educational “optimization” guides. forum
- Standard micro optimization charts: ~200–300 mcg once daily morning; cycle lengths in this family often ~4–8 weeks or ~1–2 months with multi-week to multi-month breaks. forum
- Long micro courses (minority vs classic bioregulator blocks): Some protocol pages list ~8–12 or ~8–16 week daily 100–300 mcg courses — more research-chem invention than classic Khavinson 10–20 day culture. forum
- Classic short high course (Khavinson / Russian bioregulator convention): ~1–2 mg per day subcutaneous or IM × ~10–20 consecutive days from common 20 mg lyophilized vials. forum
- Clinic-education low-milligram frameworks: Some clinician-facing posts cite low-mg daily ranges (occasionally ~10 mg/day-class language for specific compounded preparations/routes) for 10–20 day cycles, 2–4×/year — formulation-dependent and not interchangeable with gray-market mcg charts. forum
- EOD / MWF minority: Forum self-reports include ~2 mg every 3 days or Mon/Wed/Fri for ~1 month on / 1 month off — not a standard chart. anecdote
- Oral Cytogen / capsule protocols: Commonly discussed as ~1–2 capsules once or twice daily (often before meals) for ~20–30 days or ~1 month; some sources say one capsule BID with food. Exact mg of pure KEDG per capsule varies by brand and is often not pure free peptide. forum
- Oral → extract sequencing: Some practitioner protocols run oral Testagen course then transition to Testoluten (natural testicular extract) for “continued support” — product sequencing lore, not a registration trial. forum
- Sublingual / oral-spray mention: Clinic-education posts list sublingual or spray forms as bioavailability-seeking options for short peptides; dedicated Testagen PK comparing swallow vs SL vs SC is sparse. forum
- Unit-error warning: Mixing a 100–300 mcg chart with a 1–2 mg chart on the same vial math swings volume 10×+; 20 units ≠ 20 mcg. forum
- Timing: Morning subq most common (circadian hormone-rhythm lore); oral sometimes split with meals or before meals. forum
- Yearly / course pattern: Short courses ~2–4× per year with ~3–6 months between blocks dominate bioregulator culture; continuous open-ended daily use is uncommon. forum
- Injectable low / titration band (dominant Western research-chem charts): ~100–300 mcg subcutaneous once daily. Common step charts: start ~100 mcg → ~150 mcg → standard ~200 mcg → optional ~250–300 mcg. forum
- Animal / dish doses are not human recipes: Avian hypophysectomy and micromolar in-vitro work cannot be linearly scaled to multi-mg SubQ charts. animal
- Framing: Community, vendor-chart, and clinic-education ranges only — not advice, not prescriptions, not FDA-labeled dosing. Ranges disagree by orders of magnitude (low-hundreds of mcg vs multi-mg); treat that disagreement as a core fact. forum
How it may feel
- Days 1–3: Little acute “kick” for most; no instant libido or androgenic pump. Occasional mild early fatigue/flatness or injection-site noise. forum
- Days 4–10: First window for mild energy, mood, or drive notes on classic 10–20 day blocks — still subtle vs TRT. forum
- Weeks 3 to about 3 months: One same-author thread described higher energy, libido and gym strength while the poster reported 2 mg Monday/Wednesday/Friday, then 2 mg every three days, and at about three months Monday/Wednesday/Friday again. The poster said total testosterone remained in the low 700s despite feeling better, while also using Reta, CJC/Ipamorelin, MOTS-c and occasional BPC/TB-500. anecdote
- Weeks 2–4 on longer mcg charts: Some Western research-chem logs wait for subjective change deeper into 4–8 week daily-micro courses before judging. forum
- Hormonal-effect horizon (community expectation): Pepbase-style writeups and clinic pages often say noticeable endocrine-adjacent effects may land around weeks 4–8 if at all — bioregulator pace, not same-week serum fireworks. forum
- Days–weeks post-course: Residual libido/energy “after the course” lore is common in bioregulator culture even after blood exposure should be gone. anecdote
- Months 3–6: Re-run talk on a ~2–4×/year calendar or when low-T symptoms return; not continuous daily forever. forum
- Lab-minded users: Baseline + post-course total/free T, LH/FSH, TSH/free T3/T4, SHBG, ± estradiol; 3–6 month re-eval horizons appear in clinic-education posts more than week-1 blood draws. forum
Cycles people discuss
- Classic bioregulator block: ~10–20 consecutive days daily (especially at 1–2 mg or oral-course culture). forum
- Oral capsule block: ~20–30 days or ~1 month courses common in Cytogen-style product talk. forum
- Western micro block: ~4–6 weeks initially, or ~1–2 months at 100–300 mcg/day, then break. forum
- Long micro minority: ~8–12 or ~8–16 week daily charts with multi-month offs. forum
- Off periods (classic): Every ~3–6 months between courses (~2–4× yearly). forum
- Equal on/off micro talk: Some guides pair ~4–6 weeks on with similar-length off, or 1 month on / 1 month off (EOD reports). forum
- Not continuous daily forever: Proposed mechanism is a transcriptional “nudge”; originator and clinic culture favor intermittent courses over year-round daily injection. forum
- Re-runs: Seasonal, calendar-based, or when low-T / energy symptoms return; multi-year controlled safety databases for gray-market synthetic KEDG do not exist. forum
- Judge horizon: Subjective energy/libido within or shortly after a course; lab changes if any judged over longer (weeks–months) windows, not day-3 bloods. forum
Timing
- Forum / aggregator PK claims: Secondary pages sometimes list ~15 min to peak, ~30 min half-life, and ~2.5 h clearance-class figures — treat as unvalidated secondary claims, not a registration PK study. forum
- Why short courses anyway: Gene-expression / bioregulator “programming” narrative and Russian course tradition drive 10–20 day bursts more than depot half-life math. forum
- After course: Claimed libido/energy residual weeks past blood exposure is common bioregulator lore (anecdote). anecdote
- Timing culture: Morning inject preferred to “align with natural hormone rhythms”; evening less common unless stacked with night-dosed Epitalon. forum
- Oral absorption uncertainty: Relative human oral vs injectable bioavailability for Testagen specifically is not precisely established; inject is preferred in potency-seeking research-chem talk. forum
- PK honesty: No formal modern public human plasma half-life / clearance package for synthetic KEDG is the standard reference — dosing culture is not true PK-driven. trial
- Structural expectation: Small linear unprotected tetrapeptide → rapid peptidase breakdown and short systemic presence expected. trial
More on what it is
- Name trap: “Testa-” refers to testis tissue modeling in the bioregulator tradition — not to testosterone the hormone. It is not a steroid, SARM, SERM, hCG, or exogenous T product. forum
- Why people search it: Age-related low-T, libido, and “support natural production without TRT” threads; also dual thyroid–testosterone optimization talk in peptide forums and clinic marketing. forum
- Critical product split: Synthetic Testagen (KEDG) ≠ Testoluten (natural testicular polypeptide extract). Extract and synthetic have different evidence bases; doses from one should not be read as validated for the other. forum
- Research lens: Match any “% T increase” claim to form (oral Cytogen capsule vs research lyophilized vial), route, cycle length, labs, and stack confounds. forum
- What it is: Synthetic tetrapeptide L-Lys–L-Glu–L-Asp–Gly (one-letter KEDG), ~447.4 g/mol (C17H29N5O9), from Vladimir Khavinson’s short-peptide bioregulator line (St. Petersburg Institute of Bioregulation and Gerontology lineage). Research-only / not FDA-approved in the US. trial
- Mechanism talk: Short peptides that may cross cell/nuclear membranes, interact with DNA/histones, and modulate gene expression in endocrine tissues; vendor and review writeups emphasize anterior pituitary (TSH) and downstream T3/T4, with secondary testosterone-normalization narratives. trial
- Evidence posture: Older Russian clinical and product literature plus avian hypophysectomy / thyroid morphology work and in-vitro DNA-interaction studies; few modern independent Western RCTs on synthetic KEDG for fertility, sperm parameters, or hard T endpoints. trial
- Also not: Testagen™ TDS®-Testosterone (a branded testosterone transdermal formulation studied under that trade name) — same word, unrelated molecule. trial
Stacks
- Testoluten (sequence): Oral Testagen course then natural testicular extract Testoluten for “maintenance” — common bioregulator-clinic lore; products are not interchangeable. forum
- Epitalon / Epithalon (longevity dual): Same calendar window or overlapping courses; example community template: Testagen ~100–200 mcg morning + Epitalon ~100–200 mcg evening × ~4–6 weeks, then off. Attribution of any benefit is confounded. forum
- Thymalin: Immune + endocrine dual for aging or chronic prostatitis-style narratives. forum
- Prostamax: Same course window for urogenital-directed Khavinson short-peptide pairing. forum
- Pinealon / other Cytogens: Full longevity “organ pack” talk (brain + pineal + testes). forum
- HPG pharma adjuncts: Enclomiphene, kisspeptin analogs, or hCG co-discussed in “natural T” stacks — confounds labs and credit. forum
- GHRH-class: CJC-1295 / tesamorelin-class peptides when concurrent somatotropic support is the separate goal. forum
- BPC-157: Injury/inflammation + hormone optimization dual — mechanism-unrelated stack, popular in general peptide culture. forum
- vs Gonadorelin / kisspeptin alone: Those push HPG pharmacologically; Testagen is framed as gentler epigenetic/bioregulator “reset” — different mental model, not a proven superiority trial. forum
- Lifestyle always gets credit: Sleep, resistance training, body-fat reduction, less alcohol — often the real driver when stacked. forum
- PCT minority talk: Some bodybuilding posts float Testagen in post-cycle recovery stacks; evidence is anecdote-level and confounded by SERMs/hCG. anecdote
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection site: Redness, itch, swelling, or tenderness — the most consistently noted community effect for SubQ bioregulator use; usually short-lived with rotation and sterile technique. forum
- Mild systemic: Transient headache, lightheadedness, or early-cycle fatigue/“flatness” — infrequent, anecdotal. forum
- Appetite: Increased hunger noted in some guides — may relate to metabolic/thyroid talk; diet confounds apply. anecdote
- Mood / libido noise: Occasional mood swings, irritability, or libido shifts (usually framed positive; can go the other way with misuse lore). anecdote
- Hormonal fluctuation caution: Misuse/overuse narratives include temporary sexual-performance dips or mood swings from “pushing” endocrine axes without labs. forum
- Thyroid interaction risk: Theoretical interference with levothyroxine or other thyroid meds if TSH/T3/T4 shift; community harm-reduction says monitor if on thyroid drugs. forum
- Contraindication talk (community/clinic lists): Active malignancy, thyroid cancer, hyperthyroidism, pregnancy/breastfeeding, known hypersensitivity; extreme caution in hormone-sensitive cancers (e.g. prostate). forum
- Not androgenic like TRT: Does not carry classic steroid sides (acne, HCT rise, aromatization, HPTA shutdown) as its primary profile — but that is not proof of risk-free use. forum
- Source / quality risk: Gray-market mislabel, underdosing, contamination, non-sterile vials; demand HPLC/MS COA identity for KEDG. forum
- Not a substitute for workup: Skipping evaluation of real hypogonadism, infertility, pituitary disease, or thyroid disease is a misuse risk. forum
- Thin modern safety package: No large Phase I–III Western package for synthetic research-chem KEDG; “no sides” marketing claims ≠ controlled adverse-event data. trial
- Trade-name collision: Do not confuse research peptide Testagen with Testagen™ TDS®-Testosterone (exogenous testosterone delivery study) when reading PubMed/HRA titles. trial
- Regulatory: Not FDA-approved as a therapy; research-only labeling on most Western vendor vials. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.